MacroGenics Stock - Thursday technical snapshot after strong year-to-date rebound
18.06.2026 - 18:07:13 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 16:30 UTC. Details in the imprint.
MacroGenics (US5562221046) is one of the biotech names that has staged a notable rebound in 2026. With no fresh company or regulatory news on Thursday, the focus shifts to how the stock is positioned technically and what the calendar looks like into August.
All news and key data on MacroGenics stock
Stay on top of MacroGenics with recent company announcements, price data and background on its antibody pipeline.
What recent data show
MacroGenics stock trades on the Nasdaq under the ticker MGNX. Quote data from MarketBeat show a closing price of $3.96 on 06/17/2026, up 2.1% on the day, with the after-hours indication unchanged at $3.96.
According to the same data set, MacroGenics shares started the year at $1.61 and have since advanced more than 150%, with the stock recently quoted around $4.00. That move has pulled the name firmly off its 2025 lows and back onto more watchlists.
Thursday focus on the chart
On Thursday, the technical picture matters more than fresh headlines. At roughly $4.00 per share, MacroGenics trades well above its early-2026 levels and is consolidating gains made after the spring earnings update.
Against this backdrop, many traders are watching how the stock behaves around recent closing prices and whether liquidity remains robust around current levels. Volatility is not unusual for small and mid-cap biotech names, and MacroGenics fits that profile.
Analyst estimates into August
MacroGenics last reported quarterly numbers on 05/13/2026. The company posted a first-quarter 2026 loss per share of $0.58, slightly wider than the consensus estimate of a $0.57 loss, on revenue of $20.78 million.
MarketBeat data currently point to an estimated date of 08/13/2026 for the next quarterly earnings release, based on the company’s historical reporting pattern. The implied August update will give investors fresh insight into cash burn, collaboration revenue and any pipeline milestones.
How MacroGenics makes money
MacroGenics is a clinical-stage biopharmaceutical company that develops monoclonal antibody-based therapies for cancer and autoimmune diseases. Its pipeline has included candidates such as mavrilimumab and various bispecific antibody constructs targeting solid tumors and hematologic malignancies.
Where the stock trades today
MacroGenics shares (US5562221046) trade on the Nasdaq at $3.96 as of 06/17/2026, 04:00 PM Eastern Time, based on the latest available closing data.
Key facts on MacroGenics stock
- Company: MacroGenics, Inc.
- ISIN: US5562221046
- WKN: A1XG7D
- Ticker: MGNX
- Venue: Nasdaq
- Price (as of 06/17/2026, 04:00 PM ET): 3.96 USD
- Market cap: 250.0 million USD (as of 06/17/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: none of the major benchmarks such as the S&P 500
- Next earnings date: 08/13/2026 (estimated)
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
